PLX Stock - Protalix BioTherapeutics, Inc.
Unlock GoAI Insights for PLX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $53.40M | $65.49M | $47.64M | $38.35M | $62.90M |
| Gross Profit | $29.08M | $42.51M | $28.05M | $22.00M | $52.02M |
| Gross Margin | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% |
| Operating Income | $3.92M | $10.46M | $-13,014,000 | $-20,462,000 | $2.71M |
| Net Income | $2.93M | $8.31M | $-14,927,000 | $-27,582,000 | $-6,523,000 |
| Net Margin | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% |
| EPS | $0.04 | $0.12 | $-0.31 | $-0.62 | $-0.22 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Visit WebsiteEarnings History & Surprises
PLXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $0.04 | — | — | — |
Q4 2025 | Nov 13, 2025 | $0.06 | $0.03 | -50.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $0.03 | $0.00 | -93.3% | ✗ MISS |
Q2 2025 | May 9, 2025 | $0.08 | $-0.05 | -162.5% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $0.07 | $0.09 | +28.6% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $0.06 | $0.03 | -50.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.01 | $-0.03 | -250.1% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-0.02 | $-0.06 | -200.0% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.03 | $-0.07 | -133.3% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $0.03 | $0.21 | +624.9% | ✓ BEAT |
Q2 2023 | May 4, 2023 | — | $-0.05 | — | — |
Q1 2023 | Feb 27, 2023 | $-0.15 | $-0.07 | +53.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.15 | $-0.07 | +53.3% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.18 | $-0.11 | +38.9% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.11 | $-0.14 | -27.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.12 | $-0.09 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.08 | $-0.25 | -212.5% | ✗ MISS |
Latest News
Protalix Biotherapeutics Announced A Collaboration With Secarna Pharmaceuticals For The Discovery Of Novel Antisense Oligonucleotide Therapies Against Multiple Targets For Rare Renal Indications, Deal Terms Were Not Disclosed
📈 PositiveHC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Lowers Price Target to $12
➖ NeutralProtalix BioTherapeutics Q3 EPS $0.03 Misses $0.06 Estimate, Sales $17.673M Miss $17.866M Estimate
📉 NegativeProtalix BioTherapeutics Unit Requests Reexamination Of Negative Opinion Issued By CHMP Related To Proposed Dosing Regimen Of 2 Mg/kg Body Weight Infused Every 4 Weeks For Elfabrio
📉 NegativeProtalix BioTherapeutics Says CHMP Denies Approval For Every-4-Week Elfabrio Regimen in EU; Maintains 2-Week Dosing Status Quo
📉 NegativeProtalix Revenue Jumps 16 Percent in Q2
📈 PositiveFrequently Asked Questions about PLX
What is PLX's current stock price?
What is the analyst price target for PLX?
What sector is Protalix BioTherapeutics, Inc. in?
What is PLX's market cap?
Does PLX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PLX for comparison